SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.740
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
1.768
+0.028 (1.60%)
After-hours: Dec 5, 2025, 7:59 PM EST
SLS Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -25.94 | -30.88 | -37.34 | -41.3 | -20.7 | -16.76 | |
| Asset Writedown & Restructuring Costs | - | - | - | 10 | 5.7 | - | |
| Stock-Based Compensation | 1.88 | 1.56 | 2.09 | 1.73 | 1.01 | 0.58 | |
| Other Operating Activities | 0.59 | 0.56 | 0.49 | 0.13 | -4.42 | -0.11 | |
| Change in Accounts Payable | -2.31 | -2.14 | 2.3 | 1.21 | -2.51 | -0.84 | |
| Change in Unearned Revenue | - | - | - | - | -5.6 | 5.6 | |
| Change in Other Net Operating Assets | -4.84 | -4.51 | 1.04 | 4.43 | 0.5 | 1.11 | |
| Operating Cash Flow | -30.62 | -35.4 | -31.41 | -23.81 | -26.02 | -10.42 | |
| Sale (Purchase) of Intangibles | - | - | -5.5 | -4.5 | - | - | |
| Investing Cash Flow | - | - | -5.5 | -4.5 | - | - | |
| Issuance of Common Stock | 31.95 | 46.82 | 22.35 | 24.08 | 12.07 | 38.44 | |
| Repurchase of Common Stock | -0.06 | -0.06 | -0.03 | - | - | - | |
| Financing Cash Flow | 53.91 | 46.76 | 22.32 | 24.08 | 12.07 | 38.44 | |
| Net Cash Flow | 23.29 | 11.36 | -14.6 | -4.23 | -13.95 | 28.03 | |
| Free Cash Flow | -30.62 | -35.4 | -31.41 | -23.81 | -26.02 | -10.42 | |
| Free Cash Flow Margin | - | - | - | -2380.90% | -342.38% | -548.26% | |
| Free Cash Flow Per Share | -0.33 | -0.58 | -1.13 | -1.23 | -1.68 | -1.31 | |
| Levered Free Cash Flow | -22.08 | -24.25 | -28.94 | -11.87 | -18.69 | -3.6 | |
| Unlevered Free Cash Flow | -22.08 | -24.25 | -28.94 | -11.87 | -18.69 | -3.6 | |
| Change in Working Capital | -7.15 | -6.65 | 3.35 | 5.64 | -7.62 | 5.87 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.